Cholesteryl Ester Transfer Protein (CETP) Inhibitors: Is There Life After Torcetrapib?

被引：17

作者：

Neeli, Hemanth ^{[1
,2
]}

Rader, Daniel J. ^{[1
]}

机构：

[1] Univ Penn, Sch Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA

[2] Temple Univ Hosp & Med Sch, Sect Hosp Med, Philadelphia, PA 19140 USA

来源：

CARDIOLOGY CLINICS | 2008年 / 26卷 / 04期

关键词：

CETP; CETP inhibitors; Torcetrabip; HDL; Illuminate;

D O I：

10.1016/j.ccl.2008.06.005

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Despite tremendous progress made in the management of CHD, a significant number of fatal and nonfatal CHD events still occur, which leads researchers to target other modifiable risk factors for CHD including low HDL-c (high density lipoprotein cholesterol). Although the torcetrapib experience was a major blow to CETP inhibition and indeed to the entire field of HDL-targeted therapeutics, it was not fatal. The off-target effects of torcetrapib appear to be substantial and may have overridden any potential cardiovascular benefit. Despite continued uncertainty regarding the cardiovascular implications of genetic CETP deficiency and pharmacologic CETP inhibition, there remain reasons to believe in the mechanism and the possibility that clean CETP inhibitors will not only improve plasma lipids but also reduce cardiovascular risk.

引用

页码：537 / +

页数：11

共 92 条

[41] Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan - Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity [J].

Hirano, K ;

Yamashita, S ;

Nakajima, N ;

Arai, T ;

Maruyama, T ;

Yoshida, Y ;

Ishigami, M ;

Sakai, N ;

KamedaTakemura, K ;

Matsuzawa, Y .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (06) :1053-1059

[42] GENETIC CHOLESTERYL ESTER TRANSFER PROTEIN-DEFICIENCY CAUSED BY 2 PREVALENT MUTATIONS AS A MAJOR DETERMINANT OF INCREASED LEVELS OF HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL [J].

INAZU, A ;

JIANG, XC ;

HARAKI, T ;

YAGI, K ;

KAMON, N ;

KOIZUMI, J ;

MABUCHI, H ;

TAKEDA, R ;

TAKATA, K ;

MORIYAMA, Y ;

DOI, M ;

TALL, A .

JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (05) :1872-1882

[43] INCREASED HIGH-DENSITY-LIPOPROTEIN LEVELS CAUSED BY A COMMON CHOLESTERYL-ESTER TRANSFER PROTEIN GENE MUTATION [J].

INAZU, A ;

BROWN, ML ;

HESLER, CB ;

AGELLON, LB ;

KOIZUMI, J ;

TAKATA, K ;

MARUHAMA, Y ;

MABUCHI, H ;

TALL, AR .

NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (18) :1234-1238

[44] LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study [J].

Jukema, JW ;

Liem, AH ;

Dunselman, PHJM ;

van der Sloot, JAP ;

Lok, DJA ;

Zwinderman, AH .

CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (11) :1865-1874

[45] Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study [J].

Jungers, P ;

Massy, ZA ;

Khoa, TN ;

Fumeron, C ;

Labrunie, M ;

Lacour, B ;

Descamps-Latscha, B ;

Man, NK .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (12) :2597-2602

[46] Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia [J].

Kastelein, John J. P. ;

van Leuven, Sander I. ;

Burgess, Leslie ;

Evans, Greg W. ;

Kuivenhoven, Jan A. ;

Barter, Philip J. ;

Revkin, James H. ;

Grobbee, Diederick E. ;

Riley, Ward A. ;

Shear, Charles L. ;

Duggan, William T. ;

Bots, Michiel L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (16) :1620-1630

[47] Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial [J].

Keech, A ;

Simes, RJ ;

Barter, P ;

Best, J ;

Scott, R ;

Taskinen, MR ;

Forder, P ;

Pillai, A ;

Davis, T ;

Glasziou, P ;

Drury, P ;

Kesäniemi, YA ;

Sullivan, D ;

Hunt, D ;

Colman, P ;

d'Emden, M ;

Whiting, M ;

Ehnholm, C ;

Laakso, M .

LANCET, 2005, 366 (9500) :1849-1861

[48] ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation [J].

Kennedy, MA ;

Barrera, GC ;

Nakamura, K ;

Baldán, A ;

Tarr, P ;

Fishbein, MC ;

Frank, J ;

Francone, OL ;

Edwards, PA .

CELL METABOLISM, 2005, 1 (02) :121-131

[49] Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS) [J].

Klerkx, AHEM ;

de Grooth, GJ ;

Zwinderman, AH ;

Jukema, JW ;

Kuivenhoven, JA ;

Kastelein, JJP .

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2004, 34 (01) :21-28

[50] Haplotype analysis of the CETP gene:: not TaqIB, but the closely linked-629C→A polymorphism and a novel promoter variant are independently associated with CETP concentration [J].

Klerkx, AHEM ;

Tanck, MWT ;

Kastelein, JJP ;

Molhuizen, HOF ;

Jukema, JW ;

Zwinderman, AH ;

Kuivenhoven, JA .

HUMAN MOLECULAR GENETICS, 2003, 12 (02) :111-123

← 1 2 3 4 5 6 7 8 9 10 →